Normanno N - Search Results

1

Gefitinib in non small cell lung cancer.

Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A. Costanzo R, et al. Among authors: normanno n. J Biomed Biotechnol. 2011;2011:815269. doi: 10.1155/2011/815269. Epub 2011 May 23. J Biomed Biotechnol. 2011. PMID: 21660144 Free PMC article. Review.

2

Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

Normanno N, Di Maio M, Perrone F, Campiglio M. Normanno N, et al. J Clin Oncol. 2004 May 15;22(10):2035-6; author reply 2036-7. doi: 10.1200/JCO.2004.99.337. J Clin Oncol. 2004. PMID: 15143103 No abstract available.

3

Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?

De Luca A, Grassii M, Maiello MR, Di Maio M, Mancino M, De Maio E, Gridelli C, Perrone F, Normanno N. De Luca A, et al. Among authors: normanno n. Anticancer Res. 2004 Sep-Oct;24(5A):2985-9. Anticancer Res. 2004. PMID: 15517905 Free article.

4

Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials.

Perrone F, Di Maio M, Budillon A, Normanno N. Perrone F, et al. Among authors: normanno n. Curr Opin Oncol. 2005 Mar;17(2):123-9. doi: 10.1097/01.cco.0000155048.51919.eb. Curr Opin Oncol. 2005. PMID: 15725916 Review.

5

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F. Di Maio M, et al. Among authors: normanno n. J Cell Physiol. 2005 Dec;205(3):355-63. doi: 10.1002/jcp.20402. J Cell Physiol. 2005. PMID: 15895392 Review.

6

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

Normanno N, Campiglio M, Perrone F, De Luca A, Menard S. Normanno N, et al. Ann Oncol. 2005 Oct;16(10):1709. doi: 10.1093/annonc/mdi325. Epub 2005 Sep 8. Ann Oncol. 2005. PMID: 16150806 Free article. No abstract available.

7

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F; NCI-Naples Breast Cancer Group. Normanno N, et al. Endocr Relat Cancer. 2005 Dec;12(4):721-47. doi: 10.1677/erc.1.00857. Endocr Relat Cancer. 2005. PMID: 16322319 Review.

8

Epidermal growth factor receptor (EGFR) signaling in cancer.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Normanno N, et al. Gene. 2006 Jan 17;366(1):2-16. doi: 10.1016/j.gene.2005.10.018. Epub 2005 Dec 27. Gene. 2006. PMID: 16377102 Review.

9

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S. Normanno N, et al. J Cell Physiol. 2006 May;207(2):420-7. doi: 10.1002/jcp.20588. J Cell Physiol. 2006. PMID: 16419029

10

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.

Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G, Rossi E, De Maio E, Di Maio M, D'Aiuto G, Botti G, Normanno N, Chiodini P, Gallo C, Perrone F, de Matteis A; NCI-Naples Breast Cancer Group. Pacilio C, et al. Among authors: normanno n. Br J Cancer. 2006 May 8;94(9):1233-6. doi: 10.1038/sj.bjc.6603096. Br J Cancer. 2006. PMID: 16622454 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

372 results

Search Page

Filters